Bronchogen BR
Bioregulator tetrapeptide
Synthetic bioregulator tetrapeptide from the Khavinson programme, studied for effects on gene expression in bronchial epithelial cells.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- Bioregulator tetrapeptide
- Category
- Bioregulator Peptides
- Type
- Single compound
- Abbreviation
- BR
- Development and regulatory status
- Not approved by FDA or EMA, research-only bioregulator peptide
What researchers study
Synthetic tetrapeptide from the Khavinson short-peptide research programme, described as a bronchial-tissue regulator. Reported to bind DNA and alter gene and protein expression in bronchial epithelial cells, in studies mostly from one research network.
Research areas
- Bronchial epithelial cell ageing and differentiation markers
- Airway remodelling in rat obstructive lung models
- Peptide-DNA binding and gene-expression regulation
- Mucin and surfactant gene expression in cell culture
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- cell culture
In human bronchial epithelial cultures, the peptide altered Ki67, Mcl-1 and p53 levels, with the strongest proliferation-marker effect in late-passage cultures
- rodent
In rats with NO2-induced obstructive lung pathology, peptide treatment reduced goblet-cell hyperplasia and squamous metaplasia, restored ciliated cells and raised secretory IgA
- in vitro assay
Fluorescence assays indicated sequence-selective DNA binding, with preference for CTG-containing oligonucleotides
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
